Xenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel

October 4, 2021 10:39 AM EDT
Get Alerts XENE Hot Sheet
Price: $31.46 -6.54%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 25 | New: 90
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy and safety data from the phase 2b X-TOLE study of XEN1101 in focal epilepsy. As we noted in our initial reaction (LINK), we think these data solidify '1101 as a differentiated agent in focal epilepsy given both the efficacy (in-line with Xcopri, which exceeded our expectations) and safety/tolerability/dosing profile (better than Xcopri). To reflect this we have boosted or PoS as well as increased '1101's share within the last-line focal-seizure population, and we've decreased our discount rate modestly (to 11% from 11.5%) to reflect some derisking as the company likely advances into a pivotal trial(s)."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel